Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New appointment at Merck & Co

This article was originally published in Scrip

Executive Summary

Merck & Co has named Dr Michael Mendelsohn senior vice-president of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. He joins the company after 17 years at Tufts Medical Center in Boston. He was the founder and for twelve years the executive director of the Center's Molecular Cardiology Research Institute, and for the past two years served as the first chief scientific officer at Tufts. Dr Mendelsohn will be based at Merck's site in Rahway, New Jersey, and will report to the company's senior vice-president, global scientific strategy, Dr Luciano Rossetti.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC009355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel